David A. Siegel Evolus, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$10.22 - $13.94 $387,338 - $528,326	-37,900 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.22 - $11.78 $54,810 - $123,690	-10,500 Reduced 21.69%	37,900 $425,000
Q4 2021 Feb 14, 2022	SELL	$5.37 - $8.38 $178,284 - $278,216	-33,200 Reduced 40.69%	48,400 $315,000
Q3 2021 Nov 15, 2021	BUY	$7.36 - $13.67 $408,480 - $758,685	55,500 Added 212.64%	81,600 $622,000
Q2 2021 Aug 16, 2021	BUY	$8.42 - $13.96 $219,762 - $364,356	26,100 New	26,100 $330,000
Q2 2019 Aug 14, 2019	SELL	$13.19 - $28.36 $170,151 - $365,844	-12,900 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.43 - $28.91 $160,347 - $372,939	12,900 New	12,900 $291,000

163

49.1M

453K

14K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $895M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.